What Fueled The Previous Growth In The Luxturna Market?
The luxturna market has seen considerable growth due to a variety of factors.
• In recent times, the Luxturna market has experienced an XX (HCAGR). It is expected to expand from $XX million in 2024 to $XX million in 2025, at a Compound Annual Growth Rate (CAGR) of XX%.
The remarkable growth during the historical phase can be ascribed to factors like increased prevalence of retinal disorders, advancing age of the population, higher patient demand, greater efforts towards gene editing research, and rising investment in the field of biotechnology.
What Can Be Expected from the Luxturna Market Size?
The luxturna market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the luxturna market size is projected to witness XX (FCAGR). By 2029, it is anticipated to reach a value of $XX million, growing at a compound annual growth rate (CAGR) of XX%.
This growth during the forecast period is driven by the increase in genetic screening programs, the demand for individualized medicine, the need for new drugs, the growing interest in genetic solutions, and the higher number of approvals for innovative treatments. The key market trends for the forecast period are the development in gene therapy, combination with digital health solutions, technological advancements in gene delivery, gene-editing technologies, and the integration with AI-based drug discoveries.
What Are the Critical Driver Fuelling The Luxturna Market's Growth?
The growth of the luxturna market is anticipated to be driven by the increasing incidence of genetic eye conditions. These disorders are a diverse set of inherited diseases arising from gene mutations, which affect the eye's structure or functionality, resulting in vision issues like blindness or limited vision. The escalating occurrence of these disorders can be linked to growing genetic abnormalities, the aging population, improved diagnosis techniques, and heightened understanding of inherited illnesses. Luxturna serves as a gene therapy for treating these genetic eye diseases, primarily inherited retinal diseases (IRDs) caused by mutations in the RPE65 gene, by providing a functional version of the gene, potentially curing the disease and restoring vision. For example, the United Nations Development Programme (UNDP), a US-based United Nations agency, reported in December 2023 that the number of people diagnosed with vision impairments increased from 17,478 in 2021 to 19,551 in 2022. Furthermore, more than 19,000 new diagnoses were reported in the first seven months of 2023 alone. Hence, the increasing incidence of genetic eye conditions fuels the expansion of the luxturna market.
How Is The Luxturna Market segmented?
The luxturna market covered in this report is segmented –
1) By Indication: Treatment Of RPE65-Mediated Inherited Retinal Disease, Management Of Vision Loss
2) By Patient Demographics: Pediatric Patients, Adult Patients, Patients With Early Diagnosis
3) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Ophthalmology Clinics, Specialty Pharmacies, Research Institutions
Pre-Book The Luxturna Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Luxturna Market?
One notable development in the luxturna market is the initiation of real-world investigations surrounding its gene therapies like the adeno-associated virus vector-based gene therapy to foster an image of transparency and dedication to patient outcomes. The adeno-associated virus (AAV) vector-based gene therapy employs an altered virus to convey therapeutic genes to cells, offering a possible treatment for genetic diseases such as RPE65-related retinal dystrophy. For example, in April 2023, Spark Therapeutics, a US biotechnology firm focusing on gene therapy treatments shared real-world figures for Luxturna (voretigene neparvovec), an AAV-based gene therapy for RPE65-related inherited retinal dystrophy (IRD), featuring eight Belgian patients at the ARVO 2023 Annual Meeting. Of the 15 eyes treated in this observational study, there were substantial enhancements in light sensitivity noted 6 months after treatment for red, blue, and white light, alongside an advanced visual field (object III4). Two years after treatment, Luxturna registered an average difference of -0.03 BCVA and -13.67 decibels in the full-field light sensitivity threshold. Concerning safety, 35% of patients had at least one ocular adverse happening, with the most frequently reported being chorioretinal atrophic changes in 13 instances.
Who Are the Key Players In The Luxturna Market?
Major companies operating in the luxturna market include:
• F. Hoffmann-La Roche AG
What Is The Most Dominant Region In The Luxturna Market?
North America was the largest region in the luxturna market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the luxturna market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
